Literature DB >> 34550422

Interactions between islets and regulatory immune cells in health and type 1 diabetes.

Matthew A Budd1,2, Mahdis Monajemi1,2, Sarah J Colpitts3,4, Sarah Q Crome3,4, C Bruce Verchere1,2,5, Megan K Levings6,7,8.   

Abstract

Type 1 diabetes results from defects in immune self-tolerance that lead to inflammatory infiltrate in pancreatic islets, beta cell dysfunction and T cell-mediated killing of beta cells. Although therapies that broadly inhibit immunity show promise to mitigate autoinflammatory damage caused by effector T cells, these are unlikely to permanently reset tolerance or promote regeneration of the already diminished pool of beta cells. An emerging concept is that certain populations of immune cells may have the capacity to both promote tolerance and support the restoration of beta cells by supporting proliferation, differentiation and/or regeneration. Here we will highlight three immune cell types-macrophages, regulatory T cells and innate lymphoid cells-for which there is evidence of dual roles of immune regulation and tissue regeneration. We explore how findings in this area from other fields might be extrapolated to type 1 diabetes and highlight recent discoveries in the context of type 1 diabetes. We also discuss technological advances that are supporting this area of research and contextualise new therapeutic avenues to consider for type 1 diabetes.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Beta cells; Innate lymphoid cells; Macrophages; Regeneration; Regulatory T cells; Review; Type 1 diabetes

Mesh:

Year:  2021        PMID: 34550422     DOI: 10.1007/s00125-021-05565-6

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  99 in total

1.  An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.

Authors:  Kevan C Herold; Brian N Bundy; S Alice Long; Jeffrey A Bluestone; Linda A DiMeglio; Matthew J Dufort; Stephen E Gitelman; Peter A Gottlieb; Jeffrey P Krischer; Peter S Linsley; Jennifer B Marks; Wayne Moore; Antoinette Moran; Henry Rodriguez; William E Russell; Desmond Schatz; Jay S Skyler; Eva Tsalikian; Diane K Wherrett; Anette-Gabriele Ziegler; Carla J Greenbaum
Journal:  N Engl J Med       Date:  2019-06-09       Impact factor: 91.245

2.  Interleukin-33-Activated Islet-Resident Innate Lymphoid Cells Promote Insulin Secretion through Myeloid Cell Retinoic Acid Production.

Authors:  Elise Dalmas; Frank M Lehmann; Erez Dror; Stephan Wueest; Constanze Thienel; Marcela Borsigova; Marc Stawiski; Emmanuel Traunecker; Fabrizio C Lucchini; Dianne H Dapito; Sandra M Kallert; Bruno Guigas; Francois Pattou; Julie Kerr-Conte; Pierre Maechler; Jean-Philippe Girard; Daniel Konrad; Christian Wolfrum; Marianne Böni-Schnetzler; Daniela Finke; Marc Y Donath
Journal:  Immunity       Date:  2017-11-21       Impact factor: 31.745

3.  Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes.

Authors:  Manuela Battaglia; Simi Ahmed; Mark S Anderson; Mark A Atkinson; Dorothy Becker; Polly J Bingley; Emanuele Bosi; Todd M Brusko; Linda A DiMeglio; Carmella Evans-Molina; Stephen E Gitelman; Carla J Greenbaum; Peter A Gottlieb; Kevan C Herold; Martin J Hessner; Mikael Knip; Laura Jacobsen; Jeffrey P Krischer; S Alice Long; Markus Lundgren; Eoin F McKinney; Noel G Morgan; Richard A Oram; Tomi Pastinen; Michael C Peters; Alessandra Petrelli; Xiaoning Qian; Maria J Redondo; Bart O Roep; Desmond Schatz; David Skibinski; Mark Peakman
Journal:  Diabetes Care       Date:  2019-11-21       Impact factor: 19.112

4.  C-Peptide Levels in Subjects Followed Longitudinally Before and After Type 1 Diabetes Diagnosis in TrialNet.

Authors:  Magdalena M Bogun; Brian N Bundy; Robin S Goland; Carla J Greenbaum
Journal:  Diabetes Care       Date:  2020-05-26       Impact factor: 19.112

Review 5.  Islet-immune interactions in type 1 diabetes: the nexus of beta cell destruction.

Authors:  L Peters; A Posgai; T M Brusko
Journal:  Clin Exp Immunol       Date:  2019-08-14       Impact factor: 4.330

6.  Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients.

Authors:  Ken T Coppieters; Francesco Dotta; Natalie Amirian; Peter D Campbell; Thomas W H Kay; Mark A Atkinson; Bart O Roep; Matthias G von Herrath
Journal:  J Exp Med       Date:  2012-01-02       Impact factor: 14.307

Review 7.  Beta cells in type 1 diabetes: mass and function; sleeping or dead?

Authors:  Richard A Oram; Emily K Sims; Carmella Evans-Molina
Journal:  Diabetologia       Date:  2019-02-14       Impact factor: 10.122

8.  Increased β-cell proliferation before immune cell invasion prevents progression of type 1 diabetes.

Authors:  Ercument Dirice; Sevim Kahraman; Dario F De Jesus; Abdelfattah El Ouaamari; Giorgio Basile; Rocky L Baker; Burcu Yigit; Paul D Piehowski; Mi-Jeong Kim; Alexander J Dwyer; Raymond W S Ng; Cornelia Schuster; Heidrun Vethe; Tijana Martinov; Yuki Ishikawa; Adrian Kee Keong Teo; Richard D Smith; Jiang Hu; Kathryn Haskins; Thomas Serwold; Wei-Jun Qian; Brian T Fife; Stephan Kissler; Rohit N Kulkarni
Journal:  Nat Metab       Date:  2019-05-06

Review 9.  Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report.

Authors:  Diane K Wherrett; Jane L Chiang; Alan M Delamater; Linda A DiMeglio; Stephen E Gitelman; Peter A Gottlieb; Kevan C Herold; Daniel J Lovell; Trevor J Orchard; Christopher M Ryan; Desmond A Schatz; David S Wendler; Carla J Greenbaum
Journal:  Diabetes Care       Date:  2015-10       Impact factor: 19.112

10.  Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes.

Authors:  Sarah J Richardson; Teresa Rodriguez-Calvo; Ivan C Gerling; Clayton E Mathews; John S Kaddis; Mark A Russell; Marie Zeissler; Pia Leete; Lars Krogvold; Knut Dahl-Jørgensen; Matthias von Herrath; Alberto Pugliese; Mark A Atkinson; Noel G Morgan
Journal:  Diabetologia       Date:  2016-08-09       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.